Amedisys
AMED
AMED was delisted on the 14th of August, 2025.
283 hedge funds and large institutions have $2.86B invested in Amedisys in 2024 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 87 increasing their positions, 114 reducing their positions, and 36 closing their positions.
8% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 36
1% less funds holding
Funds holding: 287 → 283 (-4)
2.42% less ownership
Funds ownership: 97.34% → 94.92% (-2.4%)
5% less capital invested
Capital invested by funds: $3.02B → $2.86B (-$162M)
15% less funds holding in top 10
Funds holding in top 10: 13 → 11 (-2)
24% less repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 114
84% less call options, than puts
Call options by funds: $12.8M | Put options by funds: $81.8M
Top Buyers
Top Sellers
AMED Hedge Fund Activity: Q1 2024 in Review
283 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q1 2024, worth a combined $2.86B — down 5.4% from $3.02B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of AMED and 33 opened new positions — a net loss of 3 holders — while 114 trimmed existing stakes and 87 added.
The largest buyer was Farallon Capital Management, adding an estimated $30.2M. The largest seller was Vaughan Nelson Investment Management, exiting entirely with an estimated $27.2M sold.
- 283 institutional investors held Amedisys (AMED) as of Q1 2024, down from 287 in Q4 2023.
- Funds reported $2.86B of Amedisys stock for Q1 2024, down 5.4% quarter-over-quarter.
- 33 funds opened new Amedisys positions in Q1 2024 and 36 closed out, a net change of -3 holders.
- The largest Amedisys buyer in Q1 2024 was Farallon Capital Management, an estimated $30.2M added.
- The largest Amedisys seller in Q1 2024 was Vaughan Nelson Investment Management, an estimated $27.2M sold.
Based on aggregated 13F filings for Q1 2024.